The panel discusses the role of antibody-drug conjugates (ADCs) and the treatment of patients with HER2-mutated non–small cell lung cancer.
FDA Grants Breakthrough Therapy Designation to NVL-655 for Pretreated ALK+ NSCLC
Lunning and Herrera Highlight Frontline Hodgkin Lymphoma Management Strategies
FDA Grants Accelerated Approval to Tarlatamab for ES-SCLC
Simeone and Fakih Detail Research Objectives With A2B530 in CEA-Expressing Solid Tumors
OncLive’s April Roundup of Key FDA Decisions in Oncology
Applying the Heterogeneous Approach From NSCLC to SCLC
Dr Liu Previews ASCO 2024 Lung Cancer Data
Dr Rajkumar Previews ASCO 2024 Data in Multiple Myeloma
Ribociclib Plus NSAI Maintains Manageable Safety Profile in HR+/HER2– Early Breast Cancer
Novel CDK4 Inhibitor Shows Activity and Safety in HR+/HER2– Metastatic Breast Cancer